Brittany Jepson
Medical · White House, TNNPI 1215025895
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,750, 4.0 times the $435 reported in 2021.
Across 313 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Pfizer$510
- Lilly USA, LLC$493
- AstraZeneca$261
- GSK$245
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,333100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $1,084 |
| AbbVie | 76 | $1,067 |
| Pfizer | 30 | $510 |
| Lilly USA, LLC | 38 | $493 |
| AstraZeneca | 11 | $261 |
| GSK | 14 | $245 |
| Otsuka America Pharmaceutical, Inc. | 11 | $207 |
| Phathom Pharmaceuticals, Inc. | 8 | $138 |
| Amgen(2 entities) | 8 | $137 |
| Exact Sciences | 8 | $122 |
| Boehringer Ingelheim | 4 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| Astellas Pharma US Inc | 4 | $85 |
| Johnson & Johnson(2 entities) | 5 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $72 |
| Corcept Therapeutics | 3 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $71 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Boston Scientific | 2 | $59 |
| Lundbeck LLC | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Merck | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Dexcom, Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Philips North America LLC | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,333 in reported general payments places this provider in the 85th percentile of 480 medical providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $168,169 |
| MounjaroTirzepatide | 62 | $83,039 |
| EliquisApixaban | 87 | $70,744 |
| JardianceEmpagliflozin | 65 | $54,006 |
| FarxigaDapagliflozin Propanediol | 50 | $46,116 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 27 | $45,092 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $33,050 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $32,308 |
| JanuviaSitagliptin Phosphate | 43 | $29,328 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $25,568 |
| TrulicityDulaglutide | 17 | $25,345 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $23,406 |
| XareltoRivaroxaban | 25 | $21,592 |
| MyrbetriqMirabegron | 20 | $18,070 |
| GemtesaVibegron | 15 | $15,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,084 | $178,104128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $493 | $108,38579 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $112 | $99,09792 claims |
| PfizerEliquis | $510 | $70,74487 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $261 | $69,52285 claims |
| GSKTrelegy Ellipta | $245 | $32,30835 claims |
| MerckJanuvia | $35 | $29,32843 claims |
| Johnson & JohnsonXarelto | $85 | $21,59225 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $18,07020 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $37 | $15,46715 claims |
| AbbVieLinzess, Synthroid | $1,067 | $9,42355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 480 medical providers in Tennessee.
Other medical in White House
- Maria WoodChattanooga$130K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Stephanie HowardKnoxville$18K
- Evan HatfillNashville$18K
- Meredith McDanielChattanooga$17K
- Janet BreedingKnoxville$15K
- Paul MabenKnoxville$13K
- Hannah KirkGreeneville$13K
- Scarlett FordNashville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.